58546-56-8
基本信息
北五味子提取物
五味子酯甲(标准品)
五味子酯甲, 来源于五味子
北五味子提取物,五味子酯甲(标准品)
五味子酯甲SCHISANTHERIN A
SCHISANTHERIN A 五味子酯甲
SCHISANTHERIN A 五味子酯甲 标准品
SCHISANTHERINGOMISIN
Gomisin C(Schisantherin A)
Schisantherin A (Gomisin-C
SCHISANTHERIN A 98.0% BY HPLC
Gomisin, 98%, from Schisandra chinensis
(5S,6S,7S,13aS)-5,6,7,8-Tetrahydro-1,2,3,13-tetramethoxy-6,7-dimethylbenzo[3,4]cycloocta[1,2-f]
Benzo[3,4]cycloocta[1,2-f][1,3]benzodioxole-5,6-diol, 5,6,7,8-tetrahydro-1,2,3,13-tetramethoxy-6,7-dimethyl-, 5-benzoate, (5S,6S,7S,13aS)-
(5S,6S,7S)-6-Hydroxy-1,2,3,13-tetramethoxy-6,7-dimethyl-5,6,7,8-tetrahydrobenzo[3',4']cycloocta[1',2':4,5]benzo[1,2-d][1,3]dioxol-5-yl Benzoate
物理化学性质
| 熔点 | 110～112℃ |
| 沸点 | 675.6±55.0 °C(Predicted) |
| 密度 | 1.33±0.1 g/cm3(Predicted) |
| 储存条件 | Inert atmosphere,Store in freezer, under -20°C |
| 溶解度 | 可溶于氯仿（轻微）、甲醇（轻微、超声处理） |
| 酸度系数(pKa) | 13.70±0.60(Predicted) |
| 形态 | 固体 |
| 颜色 | 白色至灰白色 |
| 水溶解性 | 不溶于水 |
安全数据
| 危险性符号(GHS) |  GHS07 |
| 警示词 | 警告 |
| 危险性描述 | H302-H315-H319-H335 |
| 防范说明 | P261-P305+P351+P338 |
| 安全说明 | 24/25 |
| 海关编码 | 29329990 |
常见问题列表
五味子果仁的乙醇提取物中分离得到去氧五味子素、五味子素、五味子乙素、五味子丙素、五味子醇乙、五味子酯甲和五味子酯乙等7个有降转氨酶活性的联苯环辛烯类木脂素。七种成份都有降低SGPT、促进肝糖元生成和延长戊巴比妥睡眠时间的作用。五味子酯乙降SGPT作用最强，五味子醇乙促进肝糖元生成作用最显著，五味子丙素延长戊巴比妥睡眠时间作用最突出。
南五味子中木脂素类成分主要有五味子酯甲、乙、丙、丁、戊和去氧五味子素。主要是五味子酯甲，含量较高。木脂素成分除五味子酯戊外，结构式在B环上都有亚甲二氧基，都可与变色酸反应。所以用五味子酯甲为对照，测得的结果基本上反映了南五味子中总木脂素的含量。
(1) 对照品溶液的配制：取五味子酯甲对照品适量，精密称定，用甲醇配制成5mg/ml的溶液即得。
(2) 样品溶液的制备：取华中五味子 (南五味子) 果实粉末约1g，精密称定。置具塞瓶中，精密加入甲醇20ml，超声处理20min，放冷至室温，摇匀，过滤，弃去初滤液，取续滤液即得。
(3) 测定：精密吸取对照品溶液20μl，供试品溶液20μl，甲醇20μl分别置具塞试管中，水浴挥去甲醇，在三个残留物中分别各精密加入10%变色酸澄清水溶液0.5ml，浓硫酸3.0ml，蒸馏水1.5ml，摇匀，同置沸水浴中加热30min，迅速冷却，以上述甲醇管为空白，照分光光度法，在570nm波长处分别测定吸收度，计算即得。
(4) 测定结果：对不同产地的南五味子药材，按所拟定的方法操作，测得其结果。
| Target | Value |
|
NF-κB
() |
The concentrations of TNF-α and IL-6 in the supernatant of cells pretreated with 2.5 or 25 mg/L of Schisantherin A are significantly decreased compared to the LPS control group (p<0.05, p<0.01). The potential cytotoxicity of Schisantherin A is evaluated by the MTT assay after incubating cells for 24 h in the absence or presence of LPS, result shows cell viabilities are not affected by the cytokines at concentrations used (0.5, 2.5, 25 mg/L). RAW 264.7 murine macrophage cells are pre-incubated with Schisantherin A for 1 h and then stimulated with 1 mg/L LPS for 12 h. Both LPS and samples are untreated in control group. After the cell culture media are collected, nitrite and PGE 2 levels are determined, and Schisantherin A is found to reduce NO and PGE 2 production in a dose-dependent manner.
Schisantherin A, a dibenzocyclooctadiene lignan isolated from the fruit of Schisandra sphenanthera , has been reported to possess varied beneficial pharmacological effects. Schisantherin A protects lipopolysaccharide-induced acute respiratory distress syndrome in mice through inhibiting NF-κB and MAPKs signaling pathways. Pretreatment with Schisantherin A markedly ameliorates LPS-induced histopathologic changes and decreases the levels of TNF-α, IL-6 and IL-1β in the BALF. In addition, the phosphorylation of NF-κB p65, IκB-α, JNK, ERK and p38 induced by LPS are suppressed by Schisantherin A. The lung wet/dry weight ratio is evaluated at 7 h after the intranasal instillation of LPS. The results show that there are no differences between control group and Schisantherin A (40 mg/kg) group (p>0.05). LPS causes a significant increase in lung wet/dry weight ratio (p<0.01) compared with the control group. Schisantherin A dose-dependently decreases the lung wet/dry weight ratio (p<0.05) compared to those in the LPS group.